Sparrow BioAcoustics, a pioneer in the field of bioacoustic AI technology, announced that it has closed its seed financing round. The $13 million funding was led by Killick Capital, Klister Credit, and Pelorus Ventures. The closing of the round represents a major step forward for the small Canadian medical AI startup.
Sparrow is an SaMD (Software as a Medical Device), and the first medically cleared product that utilizes people’s smartphones to capture and decipher cardiac sounds. Plus, Sparrow has been in the news recently for several breakthroughs in detection of cardiac anomalies, and several medical authority clearances including FDA.
KEY QUOTES:
“The team at Sparrow pushed past numerous scientific, regulatory and business obstacles to get this stage. They have accomplished things that will lead to helping millions of people in a whole new way.”
-Killick President Mark Dobbin
“In the last 100 days, normal everyday people successfully made 30,000 medical grade heart recordings. People use the system with a 96% success rate on their first try.”
-Chief Product Officer Nadia Ivanova
“There is a future where people can screen for cardiac and pulmonary problems anywhere any time, and that future is really close now.”
-Dr. Yaroslav Shpak, Chief Medical Officer
“We have some big things on the horizon, and we are heads-down getting ready.”
-CEO Mark Attila Opauszky
